Clinical trials: HCV
Chronic Hepatitis C Infection
A Study to Evaluate Chronic Hepatitis C Infection
The purpose of this study is to evaluate the safety and efficacy of ABT-450, ritonavir and ABT-267 (ABT-450/r/ABT-267; ABT-267 also known as ombitasvir) and ABT-333 (also known as dasabuvir) co-administered with ribavirin (RBV)…
- Trial name
- NCT01716585
- Testing
- ABT-450/r/ABT-267, ABT-333, Ribavirin
- Volunteers
- 636 people
- Sponsor
- AbbVie (prior sponsor, Abbott)
Chronic Hepatitis c
Management of Patients With Hepatitis C in a Public Health Care Setting: The Punjab Model
Background and Aims: The prevalence of hepatitis C virus infection (HCV) infection in Punjab, India is 3.29%, with an estimated burden of around 650,000 viremic chronic HCV (CHC) patients.
- Trial name
- NCT03488485
- Testing
- Direct Acting Antivirals
- Where
- India
- Volunteers
- 50,000 people
- Sponsor
- Post Graduate Institute of Medical Education and Research, Chandigarh
Hepatitis C
Single and Multiple Dose Evaluation of ABT-072 and to Evaluate the Effect of Food on the Pharmacokinetics of ABT-072
To assess the safety, tolerability and pharmacokinetics of the ABT-072 tablet formulation administered as a single dose and then administered as multiple doses for 7 days.
- Trial name
- NCT00982826
- Testing
- ABT-072
- Where
- United States
- Volunteers
- 52 people, healthy volunteers welcome
- Sponsor
- Abbott
Multiplex Testing of HIV, HBV, HCV and Syphilis, HIV
Clinical Performance Evaluation of MagIA IVD-MD Multiplex Testing (HIV/HBV/HCV/Syphilis)
Performance study to evaluate the clinical performance of the In-Vitro Diagnostics Medical Device MagIA H3S (a Multiplex Point-of-Care test for the combined detection of Human Immunodeficiency Virus (HIV), Hepatitis B and C and…
- Conditions
- Multiplex Testing of HIV, HBV, HCV and Syphilis, HIV, HBV, HCV
- Trial name
- MAGICS IBCS (NCT07170748)
- Where
- 2 sites in Côte d’Ivoire, Kenya
- Volunteers
- 2,950 people, healthy volunteers welcome
- Sponsor
- MagIA Diagnostics
Chronic Hepatitis C
The Tolerability, Pharmacokinetics and Pharmacodynamics Study of HEC110114 Tablets in HCV-infected Subjects
A Phase Ib/IIa, Single Center, Randomized, open, Sofosbuvir-controlled, Multiple Ascending Dose Study to Access the Tolerability，Pharmacokinetics and Pharmacodynamics of HEC110114 Tablets in HCV-infected Subjects
- Trial name
- HEC110114 (NCT04202952)
- Testing
- HEC110114 Tablet, Sofosbuvir Tablet
- Where
- China
- Volunteers
- 24 people
- Sponsor
- Sunshine Lake Pharma Co., Ltd.
Fibrosis, Liver
Impact of Ursodeoxycholic Acid, Silymarin, Antioxidants and Colchicine on Fibrosis Regression in HCV After SVR
with the introduction of Direct-acting antiviral agents in the management of HCV, the scope of inclusion criteria had been widened to include patients with compensated cirrhosis and even in special situations patients with…
- Trial name
- fib-reversal (NCT03659058)
- Testing
- silymarin, Ursodeoxycholic Acid, Antioxidants
- Volunteers
- 400 people
- Sponsor
- Zagazig University
Hepatitis C Virus
Drug Interaction Oral Contraceptive Pill (OCP)
To assess the effects of BMS-650032 on Pharmacokinetics (PK) of ethinyl estradiol (EE) and norelgestromin (NGMN) in healthy female subjects
- Trial name
- NCT01063023
- Testing
- Ortho Tri-Cyclen®, BMS-650032
- Where
- United States
- Volunteers
- 20 people, healthy volunteers welcome
- Sponsor
- Bristol-Myers Squibb
Healthy, Hepatitis C, Chronic
A Study to Evaluate the Safety, Tolerability, and PK in Healthy Volunteers and HCV Genotype 1 Infected Patients
A Safety Study to Evaluate the Safety, Tolerability, and Pharmacokinetics in HCV Genotype 1 Infected Patients
- Trial name
- NCT01523990
- Testing
- TG-2349
- Where
- United States
- Volunteers
- 135 people, healthy volunteers welcome
- Sponsor
- TaiGen Biotechnology Co., Ltd.
Chronic Hepatitis C Virus (HCV Infection Genotype 1)
Ombitasvir/Paritaprevir/Ritonavir and Dasabuvir Co-Administered With Sofosbuvir With and Without Ribavirin in Treatment-Naive HCV Genotype 1-Infected Adults
This open-label study will evaluate the safety and efficacy of co-formulated ombitasvir/paritaprevir/ritonavir and dasabuvir co-administered with sofosbuvir with or without ribavirin administered for either 4 or 6 weeks in…
- Trial name
- NCT02399345
- Testing
- ombitasvir/paritaprevir/ritonavir, dasabuvir, sofosbuvir (SOF), ribavirin (RBV)
- Volunteers
- 10 people
- Sponsor
- AbbVie
Human Immunodeficiency Virus, Hepatitis C
Pharmacokinetic Study of Raltegravir in Human Immunodeficiency Virus/Hepatitis C Virus (HIV/VHC) Coinfected Patients With Advanced (Child-Pugh C) Hepatic Cirrhosis
Raltegravir is the first integrase inhibitor used in humans. It has been shown to be highly efficacious and well tolerated in phase III clinical trials in multidrug experienced human immunodeficiency virus(HIV)-infected patients…
- Trial name
- LIVERAL (NCT01289951)
- Testing
- Raltegravir 400 mg/12hours
- Where
- Spain
- Volunteers
- 10 people
- Sponsor
- Fundacion para la Investigacion Biomedica del Hospital Universitario Ramon y Cajal
Hepatitis C Virus
Safety and Efficacy Study in Subjects With Chronic HCV and Underlying Hemophilia
The primary objective for this study is to evaluate the proportion of subjects who achieve SVR12 (HCV RNA < LLOQ (target not detected) at post-treatment follow-up Week 12 in subjects with Genotype(GT)-1b, -4 and GT-2, -3
- Trial name
- MAGNITUDE (NCT01741545)
- Testing
- Pegylated-Interferon-lambda, Ribavirin, Daclatasvir
- Where
- 32 sites in United States, Australia and 6 more
- Volunteers
- 71 people
- Sponsor
- Bristol-Myers Squibb
Hepatitis C, HIV
Study of A Combination Pill With GS-7977 and GS-5885 for Hepatitis C in People With HIV
Background: Present treatment for hepatitis C includes the use of a weekly injection and two different pills. This treatment is associated with serious side effects.
- Trial name
- NCT01878799
- Testing
- GS-7977/GS- 5885 FDC
- Where
- United States
- Volunteers
- 50 people
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
HEPATITIS C (HCV), Hepatitis B Virus (HBV)
Community Screening and Management of Hepatitis B, C and Delta in the Mongolian Population Living in France
In Mongolia, mortality from hepatocellular carcinoma (HCC) is one of the highest in the world. Viral hepatitis is the main cause of HCC: the prevalence of hepatitis B (HBV) estimated at 11% In Mongolia, hepatitis C (HCV) at 8.5%…
- Conditions
- HEPATITIS C (HCV), Hepatitis B Virus (HBV), Hepatitis D, Hepatocellular Carcinoma (HCC)
- Trial name
- Mondelta (NCT07038863)
- Testing
- Community screening for hepatitis B, C and delta in the Mongolian population living in France
- Where
- 11 sites in France
- Volunteers
- 2,000 people
- Sponsor
- Hospices Civils de Lyon
Hepatitis C
Impact of Sofosbuvir and Daclatasvir Concentration on HCV RNA
Sofosbuvir plus daclatasvir with or without ribavirin is one of the currently recommended treatment option for chronic hepatitis C.
- Trial name
- NCT03318887
- Testing
- Sofosbuvir/daclatasvir with or without ribavirin
- Where
- France
- Volunteers
- 130 people
- Sponsor
- Hospices Civils de Lyon
Liver Fibrosis, Hepatitis C
Study of Simtuzumab in HIV and/or Hepatitis C- Infected Adults With Liver Fibrosis
The primary objective of this study is to assess the safety and tolerability of simtuzumab (formerly GS-6624) in HIV and/or hepatitis C virus (HCV)-infected adults with evidence of liver fibrosis.
- Conditions
- Liver Fibrosis, Hepatitis C, HIV, HIV/HCV Co-infection
- Trial name
- NCT01707472
- Testing
- Simtuzumab
- Where
- United States
- Volunteers
- 18 people
- Sponsor
- Gilead Sciences
Hepatitis C
Safety and Efficacy of Vaniprevir (MK7009) Administered With Pegylated-Interferon and Ribavirin (MK-7009-007)
A study to evaluate how effective different levels of Vaniprevir (MK-7009), when administered with Pegylated-Interferon (Peg-IFN) and Ribavirin, are at achieving rapid viral response (RVR) i.e., undetectable hepatitis C virus…
- Trial name
- NCT00704184
- Testing
- Comparator: Vaniprevir, Comparator: Pegylated-Interferon (Peg-IFN), Comparator: Ribavirin
- Volunteers
- 95 people
- Sponsor
- Merck Sharp & Dohme LLC
Liver Fibrosis, Hepatic Fibrosis
A Trial of IDN-6556 in Post Orthotopic Liver Transplant for Chronic HCV
This is a double-blind, multicenter study involving patients with chronic HCV infection who had a liver transplantation; developed HCV-related liver fibrosis and/or incomplete cirrhosis; achieved a sustained virologic response…
- Conditions
- Liver Fibrosis, Hepatic Fibrosis, Liver Cirrhosis, Hepatic Cirrhosis
- Trial name
- POLT-HCV-SVR (NCT02138253)
- Testing
- IDN-6556
- Where
- 35 sites in United States
- Volunteers
- 64 people
- Sponsor
- Conatus Pharmaceuticals Inc.
Chronic Hepatitis C Virus
Samatasvir (IDX719) in Combinations With Simeprevir and/or TMC647055/Ritonavir With or Without Ribavirin for 12 Weeks in Participants With Chronic Hepatitis C Infection (MK-1894-005)
Parts A and B of this study are designed to evaluate the safety, tolerability, efficacy and pharmacokinetic profiles of samatasvir and simeprevir when administered in combination with ribavirin (RBV) for 12 weeks in…
- Trial name
- NCT01852604
- Testing
- Samatasvir, Simeprevir, Ribavirin (RBV)
- Volunteers
- 143 people
- Sponsor
- Merck Sharp & Dohme LLC
HCV Infection, HIV Infections
Addressing the Cascade of Care in Vulnerable Populations With Poor Access to Healthcare in Madrid
Data on the prevalence of hepatitis C virus (HCV) for other vulnerable groups in Madrid, such as homeless persons and migrants, are scarce, and it is now necessary to implement intervention and elimination plans.
- Conditions
- HCV Infection, HIV Infections, Drug Use, HBV (Hepatitis B Virus)
- Trial name
- (UMC) (NCT04062253)
- Testing
- HCV rapid test
- Where
- Spain
- Volunteers
- 2,001 people, healthy volunteers welcome
- Sponsor
- Hospital Universitario Infanta Leonor
HIV Infections, Hepatitis C
Behavioral Intervention for HIV and HCV-Uninfected Injection Drug Users
The purpose of this study is to test whether a six-session behavioral intervention for HIV and HCV seronegative injection drug users is effective in reducing sexual and injection risk behaviors that could lead to primary HIV and…
- Trial name
- NCT00164372
- Testing
- Peer Education Intervention
- Where
- 5 sites in United States
- Volunteers
- 1,400 people, healthy volunteers welcome
- Sponsor
- Centers for Disease Control and Prevention